- |||||||||| Campath (alemtuzumab) / Sanofi, TT52CAR19 / Great Ormond Street Hospital for Children, UCART19 / Allogene Therap, Servier
SINGLE CENTRE LONG-TERM OUTCOMES OF RELAPSED/REFRACTORY PAEDIATRIC B-ALL AFTER GENOME-EDITED (Hall 3 South) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2547;
P1
Overall survival at our centre has been comparable to the wider autologous CAR19 setting, despite multiple lines of previous therapy, including CARs, Bi-specific T-cell engagers (BiTEs) and previous transplant. Notably, surviving subjects had all received augmented lymphodepletion ahead of CAR19 T cells, highlighting the importance of addressing host mediated barriers to mismatched cells for deep and rapid leukemic clearance.
- |||||||||| 90Y-besilesomab (TLX66) / Telix
Enrollment open, Trial completion date, Trial primary completion date: RITII: 90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia (clinicaltrials.gov) - Oct 3, 2023
P2, N=25, Recruiting,
Notably, surviving subjects had all received augmented lymphodepletion ahead of CAR19 T cells, highlighting the importance of addressing host mediated barriers to mismatched cells for deep and rapid leukemic clearance. Not yet recruiting --> Recruiting | Trial completion date: Jun 2024 --> Sep 2025 | Trial primary completion date: Oct 2023 --> Sep 2025
- |||||||||| GD2 CAR T / University College London, Great Ormond Street Hospital for Children
Enrollment open, CAR T-Cell Therapy: CARMIGO: CAR T Cells to Target GD2 for DMG (clinicaltrials.gov) - Sep 11, 2023
P1, N=12, Recruiting,
Not yet recruiting --> Recruiting | Trial completion date: Jun 2024 --> Sep 2025 | Trial primary completion date: Oct 2023 --> Sep 2025 Not yet recruiting --> Recruiting
- |||||||||| TT52CAR19 / Great Ormond Street Hospital for Children
Enrollment closed, Trial completion date, Trial primary completion date: PBLTT52CAR19: TT52CAR19 Therapy for B-cell Acute Lymphoblastic Leukaemia (B-ALL) (clinicaltrials.gov) - May 31, 2023
P1, N=10, Active, not recruiting,
Trial completion date: Sep 2024 --> Feb 2025 Recruiting --> Active, not recruiting | Trial completion date: Jun 2022 --> Dec 2023 | Trial primary completion date: Jun 2022 --> Dec 2023
- |||||||||| 90Y-besilesomab (TLX66) / Telix
Trial primary completion date: RITII: 90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia (clinicaltrials.gov) - May 16, 2023
P2, N=25, Not yet recruiting,
Recruiting --> Active, not recruiting | Trial completion date: Jun 2022 --> Dec 2023 | Trial primary completion date: Jun 2022 --> Dec 2023 Trial primary completion date: Jun 2023 --> Oct 2023
- |||||||||| GD2 CAR T / University College London, Great Ormond Street Hospital for Children
Trial initiation date, CAR T-Cell Therapy: CARMIGO: CAR T Cells to Target GD2 for DMG (clinicaltrials.gov) - May 15, 2023
P1, N=12, Not yet recruiting,
Trial primary completion date: Jun 2023 --> Oct 2023 Initiation date: Feb 2023 --> May 2023
- |||||||||| BE CAR7 T / Great Ormond Street Hospital for Children
Single and Combinational Multiplex Base-Edited 'Universal' CAR T Cells in a Humanised Model of Primary CD7+CD33+ AML (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_4686;
Lentiviral transduction and multiplexed base editing to remove TCR, CD52 and the shared AML/T lineage antigen CD7, enabled the generation of universal donor CAR T cells for combinational use. This data demonstrates robust activity of BE-CAR33 alone and in combination with BE-CAR7 against human CD7+CD33+AML in mice and highlights the importance of strategies that ensure complete targeting of leukemic populations.
- |||||||||| Campath (alemtuzumab) / Sanofi, TT52CAR19 / Great Ormond Street Hospital for Children
Clinical, P1 data, Journal, IO biomarker: Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia. (Pubmed Central) - Nov 2, 2022
P1
Three cell banks of TT52CAR19 T cells were generated and cryopreserved...Lymphodepletion included fludarabine, cyclophosphamide, and alemtuzumab and was followed by a single infusion of 0.8 × 10 to 2.0 × 10 CAR19 T cells per kilogram with no immediate toxicities...Other complications were within expectations, and primary safety objectives were met. This study provides a demonstration of the feasibility, safety, and therapeutic potential of CRISPR-engineered immunotherapy.
- |||||||||| GD2 CAR T / University College London, Great Ormond Street Hospital for Children
New P1 trial, CAR T-Cell Therapy: CARMIGO: CAR T Cells to Target GD2 for DMG (clinicaltrials.gov) - Sep 16, 2022
P1, N=12, Not yet recruiting,
- |||||||||| 90Y-besilesomab (TLX66) / Telix
Trial initiation date: RITII: 90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia (clinicaltrials.gov) - Mar 16, 2022
P2, N=25, Not yet recruiting,
This study provides a demonstration of the feasibility, safety, and therapeutic potential of CRISPR-engineered immunotherapy. Initiation date: Jan 2022 --> Apr 2022
- |||||||||| TT52CAR19 / Great Ormond Street Hospital for Children
Enrollment open: PBLTT52CAR19: TT52CAR19 Therapy for B-cell Acute Lymphoblastic Leukaemia (B-ALL) (clinicaltrials.gov) - Nov 24, 2020
P1, N=10, Recruiting,
Conclusions Feasibility of pre-manufacturing off-the-shelf CRISPR/Cas9 edited CAR19 T cells is demonstrated and the trial has provided first in human safety data and preliminary indications of potent anti-leukaemic activity in one of two subjects dosed. Not yet recruiting --> Recruiting
|
